Jenna Philpott

London

Featured in: Favicon

clinicaltrialsarena.com Favicon

medicaldevice-network.com Favicon

pharmaceutical-technology.com Favicon

msn.com

yahoo.com (+1) Favicon

news-medical.net Favicon

energymonitor.ai Favicon

verdict.co.uk Favicon

businessandamerica.com

Articles

Newborn screening strategy needs modernising as HHS disbands advisory committee - Pharmaceutical Technology

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April.
Newborn screening strategy needs modernising as HHS disbands advisory committee

3 weeks ago | businessandamerica.com | Jenna Philpott

After sweeping cuts to US federal health agencies, the elimination of a committee responsible for recommending newborn screening regulations is raising alarms across the healthcare and rare disease communities. The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), a federally appointed body under the US Health Resources and Services Administration (HRSA), was officially terminated in April.
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics

3 weeks ago | businessandamerica.com | Jenna Philpott

Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics. The agreement, centred on the development of RNA-based gene therapies for sensorineural hearing loss, carries a potential value exceeding $1.3bn in milestone payments. Rznomics disclosed the deal on 15 May, though financial details of the upfront payment were not shared.
Eli Lilly strikes $1.3bn gene therapy deal with Rznomics

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss. The two companies will co-develop precision RNA therapeutics for inherited hearing loss treatment. Credit: Scott Olson/Getty Images News via Getty Images. Eli Lilly is strengthening its position in genetic medicine for hearing loss through a new collaboration with South Korea-based biotech Rznomics.
FDA awards cancer drug approvals to AbbVie and MSD

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients. The FDA granted approval to both drugs on 14 May. Credit: Waldemarus/iStock via Getty Images. The US Food and Drug Administration (FDA) has approved two oncology drugs: MSD’s Welireg (belzutifan) and AbbVie’s Emrelis (telisotuzumab vedotin-tllv).
AbbVie expands siRNA push with $335m ADARx deal

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

This marks AbbVie’s second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics last year. The deal with ADARx expands AbbVie’s siRNA focus. Image credit: hapabapa / iStock Editorial via Getty Images. AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to access its small interfering RNA (siRNA) platform.
Novo Nordisk taps Septerna in $2.2bn deal for oral obesity therapies

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna. Novo Nordisk has entered a deal with Septerna for oral metabolic disorder drugs. Credit: [Victor Golmer]/[iStock Editorial/Getty Images Plus] via Getty Images. As competition continues to intensify in the obesity treatment market, Novo Nordisk has struck a collaboration and licencing deal worth up to $2.2bn with the US-based biotech Septerna.
Stylus Medicine launches with $85m to advance in vivo gene editing

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline. Stylus is developing an in vivo gene editing platform. Credit: Natali_Mis/iStock via Getty Images. Biotech startup Stylus Medicine has launched with $85m in funding to develop a new class of in vivo genetic medicines that bypass the manufacturing and delivery challenges associated with ex vivo gene editing therapies.
Pharma faces 30-day deadline under Trump’s pricing order

3 weeks ago | finance.yahoo.com | Jenna Philpott

US President Donald Trump has signed an executive order aimed at reducing prescription drug prices by linking them to what pharmaceutical companies charge in other developed nations. The policy, based on a “most favoured nation” pricing model, would require drugmakers to match the lowest prices they offer in comparable countries or face regulatory action. The order gives drug manufacturers 30 days to meet government-set price targets.
Roche plans $700m manufacturing plant in the US - Pharmaceutical Technology

3 weeks ago | pharmaceutical-technology.com | Jenna Philpott

The new site will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines. Roche’s planned facility in North Carolina will create 400 jobs. Credit: jetcityimage via Getty Images. Roche is deepening its manufacturing footprint in the US with plans to invest more than $700m in a new production facility in Holly Springs, North Carolina, aimed at supporting its pipeline of next-generation obesity drugs.